SG11201901617PA - Azole compound ophthalmic preparation - Google Patents

Azole compound ophthalmic preparation

Info

Publication number
SG11201901617PA
SG11201901617PA SG11201901617PA SG11201901617PA SG11201901617PA SG 11201901617P A SG11201901617P A SG 11201901617PA SG 11201901617P A SG11201901617P A SG 11201901617PA SG 11201901617P A SG11201901617P A SG 11201901617PA SG 11201901617P A SG11201901617P A SG 11201901617PA
Authority
SG
Singapore
Prior art keywords
azole compound
ophthalmic preparation
ophthalmic
preparation
compound ophthalmic
Prior art date
Application number
SG11201901617PA
Inventor
Zeyidan Jiapaer
Qinyuan Zheng
Original Assignee
Biotool Llc
Qinyuan Zheng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotool Llc, Qinyuan Zheng filed Critical Biotool Llc
Publication of SG11201901617PA publication Critical patent/SG11201901617PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

AZOLE COMPOUND OPHTHALMIC PREPARATION An ophthalmic pharmaceutical composition containing an azole compound, a method for preparing the same, as well as a use of the pharmaceutical composition in the preparation of an ophthalmic preparation for preventing and treating ophthalmic diseases. The ophthalmic preparation contains the azole compound at a concentration of 0.005-400 μM. (No suitable Figure) 10
SG11201901617PA 2016-08-24 2017-08-23 Azole compound ophthalmic preparation SG11201901617PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610717956.2A CN107397745A (en) 2016-08-24 2016-08-24 Azole compounds eye-drops preparations
PCT/CN2017/098662 WO2018036523A1 (en) 2016-08-24 2017-08-23 Azole compound ophthalmic preparation

Publications (1)

Publication Number Publication Date
SG11201901617PA true SG11201901617PA (en) 2019-03-28

Family

ID=60389600

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901617PA SG11201901617PA (en) 2016-08-24 2017-08-23 Azole compound ophthalmic preparation

Country Status (10)

Country Link
US (2) US20190192427A1 (en)
EP (1) EP3505170B1 (en)
JP (1) JP6890794B2 (en)
KR (1) KR20190052005A (en)
CN (2) CN107397745A (en)
AU (1) AU2017317154B2 (en)
CA (1) CA3034766A1 (en)
EA (1) EA201990550A1 (en)
SG (1) SG11201901617PA (en)
WO (1) WO2018036523A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109985071A (en) * 2017-12-29 2019-07-09 上海蓝木化工有限公司 The new application of Inonotus obliquus extract
BR112021003307A2 (en) * 2018-08-28 2021-05-11 Cloudbreak Therapeutics, Llc emulsion formulations of multikinase inhibitors
MX2021009520A (en) * 2021-08-06 2023-02-07 Foodvica S A De C V Ophthalmic composition for the treatment of visual disorders.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02290815A (en) * 1989-05-01 1990-11-30 Santen Pharmaceut Co Ltd Antifungal eye drop
AU4061599A (en) * 1998-06-10 1999-12-30 Wakamoto Pharmaceutical Co., Ltd. Aqueous preparations containing hardly soluble drug
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
CN100418530C (en) * 2005-04-06 2008-09-17 河南省眼科研究所 Ketoconazole eye drops and fabricating method thereof
CN100418536C (en) * 2005-04-06 2008-09-17 河南省眼科研究所 Ophthalmic pharmaceutical composition for resisting fungus
US20070249546A1 (en) * 2006-04-22 2007-10-25 Sawaya Assad S Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
ES2719226T3 (en) * 2007-12-04 2019-07-09 Santen Sas Compositions comprising corticosteroid prodrugs such as dexamethasone palmitate for the treatment of eye disorders
CN101766628B (en) * 2010-01-20 2012-07-04 广东宏盈科技有限公司 Ophthalmic bacterial-infection resisting medicine for external use
CN101786993A (en) * 2010-03-26 2010-07-28 复旦大学 1, 2, 3-triazole compound and application thereof in preparing indoleamine 2, 3-dioxygenase inhibitor
CN104027302B (en) * 2013-03-07 2019-04-05 中国医药工业研究总院 - 3 beta-triol eye-drops preparations of β, 7 β, 17 of 17 α-acetenyl androstane -5- alkene
JP2015093869A (en) * 2013-11-14 2015-05-18 国立大学法人東北大学 Retinal protection agent, and sustained-release device for treatment of retinal disease
CN103736093A (en) * 2013-12-27 2014-04-23 于运红 Medicinal preparation comprising mizolastine and steroid
JP6706020B2 (en) * 2014-08-22 2020-06-03 グアンチョウ カンルイ バイオロジカル ファーマシューティカル テクノロジー シーオー．，エルティーディー． Compositions and methods for treating visual disorders
WO2016029197A1 (en) * 2014-08-22 2016-02-25 Kang Zhang Compositions and methods to treat and/or prevent vision disorders of the lens of the eye

Also Published As

Publication number Publication date
EP3505170A4 (en) 2020-04-29
CN107397745A (en) 2017-11-28
EA201990550A1 (en) 2019-11-29
CN109689049B (en) 2021-04-27
AU2017317154A1 (en) 2019-04-11
JP6890794B2 (en) 2021-06-18
EP3505170A1 (en) 2019-07-03
JP2019532095A (en) 2019-11-07
US20190192427A1 (en) 2019-06-27
AU2017317154B2 (en) 2020-04-30
EP3505170B1 (en) 2021-08-11
CA3034766A1 (en) 2018-03-01
US20210330586A1 (en) 2021-10-28
CN109689049A (en) 2019-04-26
WO2018036523A1 (en) 2018-03-01
KR20190052005A (en) 2019-05-15

Similar Documents

Publication Publication Date Title
MX2019001125A (en) Macrocycle kinase inhibitors.
MX2017016655A (en) Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof.
MY195002A (en) Benzoxazepin oxazolidinone compounds and methods of use
TW201613887A (en) Antiproliferative compounds and methods of use thereof
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
WO2016044189A8 (en) Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
SG10201811128RA (en) Ezh2 inhibitors for treating lymphoma
MX2016012574A (en) Substituted heteroaryl compounds and methods of use.
MX2015012414A (en) Salt of omecamtiv mecarbil and process for preparing salt.
MY192532A (en) Liquid pharmaceutical composition
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
WO2019040106A3 (en) Compounds, salts thereof and their use in the treatment of diseases
CR20220215A (en) Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
EP3342858A4 (en) Ror1-positive mesenchymal stem cells and method for preparing same, pharmaceutical composition containing ror1-positive mesenchymal stem cells and method for preparing same, and method for preventing or treating diseases by using ror1-positive mesenchymal stem cells
EA201692481A1 (en) COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101
EP3492096A4 (en) Pharmaceutical composition for treating ocular diseases, containing cas9 protein and guide rna
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
EA201790726A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ULCERAL COLITIS
AU2016206832A8 (en) Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs
MX2016015211A (en) Topical formulations and uses thereof.
EP3138834A4 (en) Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient
SG10201811574YA (en) Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
SG11201901617PA (en) Azole compound ophthalmic preparation
CA3010788A1 (en) Methods of administering vasopressors